Two Randomized Trials of Canakinumab in Systemic Juvenile Idiopathic Arthritis

Abstract

These two phase 3 studies show the efficacy of canakinumab in systemic JIA with active systemic features. (Funded by Novartis Pharma; ClinicalTrials.gov numbers, NCT00889863 and NCT00886769.).

Keywords

CanakinumabMedicineArthritisJuvenileClinical trialMonoclonal antibodyImmunologyInternal medicineAntibodyDiseaseBiologyGenetics

Affiliated Institutions

Related Publications

The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis.

Daniel Fishman , Gary Faulds , Rachel Jeffery +4 more

During active disease, patients with systemic-onset juvenile chronic arthritis (S-JCA) demonstrate a rise and fall in serum interleukin-6 (IL-6) that parallels the classic quoti...

1998 Journal of Clinical Investigation 2233 citations

IL-6 in Inflammation, Immunity, and Disease

Toshio Tanaka , Masashi Narazaki , T Kishimoto

Interleukin 6 (IL-6), promptly and transiently produced in response to infections and tissue injuries, contributes to host defense through the stimulation of acute phase respons...

2014 Cold Spring Harbor Perspectives in Bi... 4591 citations

Lessons Learned to Date on COVID-19 Hyperinflammatory Syndrome: Considerations for Interventions to Mitigate SARS-CoV-2 Viral Infection and Detrimental Hyperinflammation

Marco Cardone , Masahide Yano , Amy S. Rosenberg +1 more

The first case of human transmission of SARS-CoV-2 was reported in China in December 2019. A few months later, this viral infection had spread worldwide and became a pandemic. T...

2020 Frontiers in Immunology 52 citations

Macrophage Activation-Like Syndrome: A Distinct Entity Leading to Early Death in Sepsis

Eleni Karakike , Evangelos J. Giamarellos‐Bourboulis

Hemophagocytic lymphohistocytosis (HLH) is characterized by fulminant cytokine storm leading to multiple organ dysfunction and high mortality. HLH is classified into familial (f...

2019 Frontiers in Immunology 295 citations

Publication Info

Year: 2012
Type: article
Volume: 367
Issue: 25
Pages: 2396-2406
Citations: 684
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Two Randomized Trials of Canakinumab in Systemic Juvenile Idiopathic Arthritis

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

684

OpenAlex

Cite This

APA Style

                            
                                
                                    Nicolino Ruperto, 
                                
                                    Hermine I. Brunner, 
                                
                                    Pierre Quartier
                                
                                et al.
                            
                            (2012). 
                            Two Randomized Trials of Canakinumab in Systemic Juvenile Idiopathic Arthritis. 
                            New England Journal of Medicine
                            , 367
                            (25)
                            , 2396-2406.
                            https://doi.org/10.1056/nejmoa1205099
                        

Identifiers

DOI: 10.1056/nejmoa1205099